Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients

Juan Palou, Oriol Angerri, José Segarra, Juan Caparrós, Luis Guirado, Juan Manuel Diaz, José Salvador-Bayarri, Humberto Villavicencio-Mavrich

Research output: Contribution to journalArticleResearchpeer-review

58 Citations (Scopus)

Abstract

Background. Intravesical instillations with bacillus Calmette-Gué rin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder. Methods. There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS. Results. Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection. Conclusions. Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.
Original languageEnglish
Pages (from-to)1514-1516
JournalTransplantation
Volume76
Issue number10
DOIs
Publication statusPublished - 27 Nov 2003

Fingerprint

Dive into the research topics of 'Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients'. Together they form a unique fingerprint.

Cite this